<DOC>
	<DOCNO>NCT00765830</DOCNO>
	<brief_summary>This clinical trial design provide additional information safety tolerability vildagliptin ( 50 mg daily ( qd ) ) use patient type 2 diabetes mellitus ( T2DM ) moderate severe renal insufficiency</brief_summary>
	<brief_title>Safety Tolerability Vildagliptin Versus Placebo Patients With Type 2 Diabetes Moderate Severe Renal Insufficiency ( 28 Week Extension )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>Complete core study Did comply core study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Type 2 diabetes , vildagliptin</keyword>
</DOC>